ELSALYS BIOTECH
Designs and develops a new generation of therapeutic antibodies targeting tumors and their immune and vascular microenvironment.
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | - | (37 %) | (60 %) | 1981 % | (98 %) | 10271 % | (2 %) |
| EBITDA | (1.9m) | (2.3m) | (3.7m) | (4.2m) | (3.6m) | (5.1m) | (4.2m) |
| % EBITDA margin | (2519 %) | (4772 %) | (18953 %) | (1045 %) | (51229 %) | (702 %) | (588 %) |
| Profit | (1.8m) | (1.9m) | (3.6m) | (4.1m) | (3.8m) | (3.6m) | (4.8m) |
| % profit margin | (2375 %) | (3840 %) | (18918 %) | (1018 %) | (54329 %) | (497 %) | (668 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
€2.1m | Series A | ||
* | N/A | Acquisition | |
| Total Funding | €2.1m | ||
Recent News about ELSALYS BIOTECH
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.